WO1992000011A3 - Antagonistes de leukotriene b?4¿ - Google Patents

Antagonistes de leukotriene b?4¿ Download PDF

Info

Publication number
WO1992000011A3
WO1992000011A3 PCT/US1991/004386 US9104386W WO9200011A3 WO 1992000011 A3 WO1992000011 A3 WO 1992000011A3 US 9104386 W US9104386 W US 9104386W WO 9200011 A3 WO9200011 A3 WO 9200011A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
leukotriene
antagonists
compounds
formula
Prior art date
Application number
PCT/US1991/004386
Other languages
English (en)
Other versions
WO1992000011A2 (fr
Inventor
Stevan Wakefield Djuric
Stephen Hermann Docter
Stella Siu-Tzyy Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Priority to CA002081766A priority Critical patent/CA2081766C/fr
Priority to EP91916271A priority patent/EP0593478B1/fr
Priority to DE69115297T priority patent/DE69115297T2/de
Priority to JP3515594A priority patent/JP2942630B2/ja
Publication of WO1992000011A2 publication Critical patent/WO1992000011A2/fr
Publication of WO1992000011A3 publication Critical patent/WO1992000011A3/fr
Priority to US07/995,859 priority patent/US5310951A/en
Priority to GR950403300T priority patent/GR3018322T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Spray-Type Burners (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

Cette invention se rapporte à des composés de formule (I) et aux stéréoisomères et aux sels pharmaceutiquement acceptables de ces composés où R représente alkyle, alcényle, alkynyle ou cycloalkylalkyle; R1 représente alkyle; R2 représente hydrogène ou alkyle; R6 représente alkyle; n représente de 1 à 5; p représente de 0 à 6; x représente 0 ou 2; et R4 et R5 sont indépendamment hydrogène ou alkyle ou forment avec N une cycloalkylamine. Les composés de formule (I) sont des antagonistes de leukotriène B4 et sont utiles comme agents anti-inflammatoires et dans le traitement de maladies où agit le LTB4.
PCT/US1991/004386 1990-06-28 1991-06-27 Antagonistes de leukotriene b?4¿ WO1992000011A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002081766A CA2081766C (fr) 1990-06-28 1991-06-27 Antagonistes du leucotriene b4
EP91916271A EP0593478B1 (fr) 1990-06-28 1991-06-27 Antagonistes de leukotriene b 4
DE69115297T DE69115297T2 (de) 1990-06-28 1991-06-27 Leukotrien-b4-antagonisten.
JP3515594A JP2942630B2 (ja) 1990-06-28 1991-06-27 ロイコトリエンb▲下4▼アンタゴニスト
US07/995,859 US5310951A (en) 1990-06-28 1992-12-23 Leukotriene B4 antagonists
GR950403300T GR3018322T3 (en) 1990-06-28 1995-12-07 Leukotriene b 4 antagonists.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/545,430 US5124350A (en) 1990-06-28 1990-06-28 Leukotriene b4 antagonists
US545,430 1990-06-28

Publications (2)

Publication Number Publication Date
WO1992000011A2 WO1992000011A2 (fr) 1992-01-09
WO1992000011A3 true WO1992000011A3 (fr) 1992-02-06

Family

ID=24176217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004386 WO1992000011A2 (fr) 1990-06-28 1991-06-27 Antagonistes de leukotriene b?4¿

Country Status (13)

Country Link
US (4) US5124350A (fr)
EP (1) EP0593478B1 (fr)
JP (1) JP2942630B2 (fr)
AT (1) ATE131165T1 (fr)
AU (1) AU8528291A (fr)
CA (1) CA2081766C (fr)
DE (1) DE69115297T2 (fr)
DK (1) DK0593478T3 (fr)
ES (1) ES2080334T3 (fr)
GR (1) GR3018322T3 (fr)
IE (1) IE62680B1 (fr)
PT (1) PT98140B (fr)
WO (1) WO1992000011A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US5488160A (en) * 1991-06-11 1996-01-30 Ciba-Geigy Corporation Amidino compounds, their manufacture and method of treatment
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US5252599A (en) * 1992-08-27 1993-10-12 Merck Frosst Canada, Inc. Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis
US5455274A (en) * 1992-12-09 1995-10-03 Ciba-Geigy Corporation Hydroxyamidine derivatives
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5516917A (en) * 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
MX9702731A (es) * 1994-10-13 1997-06-28 Pfizer Compuestos de benzopirano y benzo fusionados, composiciones que los contienen y uso de los mismos.
CA2202056A1 (fr) * 1994-10-13 1996-04-25 Mark A. Dombroski Composes de benzopyranne et composes benzo-fusionnes, leur preparation et leur utilisation comme antagonistes du leucotriene b4' (ltb4)
CA2224563A1 (fr) 1995-06-12 1996-12-27 G.D. Searle & Co. Traitement d'inflammations par une combinaison d'un inhibiteur de la cyclooxygenase-2 et d'un antagoniste du recepteur de leukotriene b4
EP1640003A2 (fr) * 1996-02-13 2006-03-29 G.D. SEARLE & CO. Compositions renfermant un inhibiteur de cyclooxygenase-2 et un antagoniste de recepteur de leucotriene b4
US6403684B1 (en) * 1998-12-16 2002-06-11 General Electric Company Polyetherimide resin/polyester resin blends having improved visual clarity
EP1324995A2 (fr) 2000-09-27 2003-07-09 Merck & Co., Inc. Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques
EP1347755A2 (fr) 2000-10-31 2003-10-01 Merck & Co., Inc. Derives d'acide benzopyranocarboxylique pour traiter le diabete et d'autres troubles lipidiques
CA2574627A1 (fr) * 2004-07-22 2006-02-02 Pharmacia Corporation Compositions pour le traitement anti-inflammatoire et anti-douleur au moyen d'une combinaison d'un inhibiteur selectif cox-2 et d'un antagoniste recepteur de ltb<sb>4</sb>
WO2006135382A2 (fr) * 2004-08-04 2006-12-21 Chemocentryx, Inc. Activites enzymatiques dans une inflammation mediee par des chimiokines
JP5154406B2 (ja) 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
US7754725B2 (en) * 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008044045A1 (fr) * 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2081891A2 (fr) * 2006-10-12 2009-07-29 Astex Therapeutics Limited COMPOSES PHARMACEUTIQUES AYANT UNE ACTIVITE INHIBITRICE OU MODULATRICE HSP90& xA;
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
EP2073804B1 (fr) 2006-10-12 2017-09-13 Astex Therapeutics Limited Composes amides d'acide benzoique substitues par un groupe hydroxyle pour son utilisation dans le traitement de la douleur
GB0806527D0 (en) * 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (fr) * 1979-09-05 1981-05-06 Glaxo Group Limited Dérivés de phénol, procédés pour leur préparation et composés pharmaceutiques les contenant
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
EP0336068A1 (fr) * 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Dérivés de phénoxyalkoxy-3,4-dihydro-2H-1-benzopyrane
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1384530A (en) * 1971-07-29 1975-02-19 Fisons Ltd Chromone derivatives
DE3070912D1 (en) * 1979-03-20 1985-09-05 Fisons Plc Pharmaceutical heterocyclic compounds, processes for their preparation and compositions containing them
US4474788A (en) * 1981-11-12 1984-10-02 Fisons Plc Anti-SRSA quinoline carboxylic acid derivatives
ZA844519B (en) * 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4665203A (en) * 1983-08-08 1987-05-12 G. D. Searle & Co. Substituted dihydrobenzopyrans useful as leukotriene D4 inhibitors
US4778903A (en) * 1983-12-12 1988-10-18 G. D. Searle & Co. Substituted dihydrobenzopyrans
US4546194A (en) * 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
US5124350A (en) * 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
DE4206523A1 (de) * 1992-03-02 1993-09-09 Vdo Schindling Vorrichtung zur verstellung einer drosselklappe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028063A1 (fr) * 1979-09-05 1981-05-06 Glaxo Group Limited Dérivés de phénol, procédés pour leur préparation et composés pharmaceutiques les contenant
US4565882A (en) * 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
EP0336068A1 (fr) * 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Dérivés de phénoxyalkoxy-3,4-dihydro-2H-1-benzopyrane

Also Published As

Publication number Publication date
EP0593478B1 (fr) 1995-12-06
IE912255A1 (en) 1992-01-01
DE69115297D1 (de) 1996-01-18
PT98140B (pt) 1998-12-31
WO1992000011A2 (fr) 1992-01-09
CA2081766C (fr) 2002-10-08
US5124350A (en) 1992-06-23
DE69115297T2 (de) 1996-06-13
GR3018322T3 (en) 1996-03-31
EP0593478A1 (fr) 1994-04-27
JP2942630B2 (ja) 1999-08-30
ES2080334T3 (es) 1996-02-01
IE62680B1 (en) 1995-02-22
US5439937A (en) 1995-08-08
CA2081766A1 (fr) 1991-12-29
US5532383A (en) 1996-07-02
PT98140A (pt) 1993-09-30
JPH05507720A (ja) 1993-11-04
ATE131165T1 (de) 1995-12-15
US5310951A (en) 1994-05-10
AU8528291A (en) 1992-01-23
DK0593478T3 (da) 1996-01-08

Similar Documents

Publication Publication Date Title
AU8528291A (en) Leukotriene b4 antagonists
NZ238092A (en) Aromatic benzopyran derivatives, preparation and pharmaceutical compositions thereof
IE830479L (en) Carboxyalkyl dipeptides
ES8702427A1 (es) Un procedimiento para preparar derivados de 1,3-difosfonato
ES8606282A1 (es) Un procedimiento de preparar derivados de acidos quinolin- ynaftiridin-carboxilicos
CA2449679A1 (fr) Androstenones
EP0408044A3 (en) Anti-inflammatory and/or anti-allergic composition comprising glutathione derivatives
GR3007401T3 (fr)
IE830278L (en) Corynanthein derivatives, anti-hypertensives
ES8702433A1 (es) Un procedimiento para la preparacion de un compuesto heterociclico sustituido con peptidos.
IE56001B1 (en) 1-arylcyclobutylmethylamine compounds
AU7892591A (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
TW333528B (en) Adhesion receptor antagonists
GR3007219T3 (fr)
AU658175B2 (en) Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
TW334428B (en) Novel benzodiazepine derivatives
CA2056793A1 (fr) 5-amino-5,6,7,8-tetrahydroquinoleines et composes apparentes; methode de preparation et utilisation comme medicaments
ES8604122A1 (es) Procedimiento de preparacion de eteres oximas basicos y de sus sales de adicion acidas farmaceuticamente aceptables
ES8500907A1 (es) Procedimiento para preparar derivados de (indenil-2)-2-imidazolina
TW275629B (fr)
EP0367036A3 (en) Substituted 3-aminosydnonimines, process for their preparation and their use
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
NZ238431A (en) ((1-arylpyrrolidin-2-yl)methyl)piperazine derivatives; pharmaceutical compositions and preparatory processes
HK34095A (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
MY101746A (en) 1,5-benzothiazepine derivatives, a process for preparing the same, pharmaceutical compositions as well as the use thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2081766

Country of ref document: CA

Ref document number: 1991916271

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1991916271

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991916271

Country of ref document: EP